EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 359 filers reported holding EXELIXIS INC in Q1 2023. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,268 | +88.1% | 58,036 | +64.6% | 0.05% | +84.0% |
| Q2 2023 | $674 | -1.5% | 35,254 | 0.0% | 0.02% | 0.0% |
| Q1 2023 | $684 | +21.1% | 35,254 | 0.0% | 0.02% | +19.0% |
| Q4 2022 | $565 | -99.9% | 35,254 | -16.8% | 0.02% | -16.0% |
| Q3 2022 | $665,000 | -9.4% | 42,390 | +20.2% | 0.02% | -7.4% |
| Q2 2022 | $734,000 | +167.9% | 35,254 | +192.2% | 0.03% | +200.0% |
| Q1 2022 | $274,000 | +80.3% | 12,066 | +45.3% | 0.01% | +80.0% |
| Q4 2021 | $152,000 | -22.1% | 8,304 | -10.1% | 0.01% | -28.6% |
| Q3 2021 | $195,000 | +16.1% | 9,240 | 0.0% | 0.01% | +16.7% |
| Q2 2021 | $168,000 | -19.6% | 9,240 | 0.0% | 0.01% | -25.0% |
| Q1 2021 | $209,000 | +13.0% | 9,240 | 0.0% | 0.01% | 0.0% |
| Q4 2020 | $185,000 | -18.1% | 9,240 | 0.0% | 0.01% | -20.0% |
| Q3 2020 | $226,000 | +3.2% | 9,240 | 0.0% | 0.01% | -9.1% |
| Q2 2020 | $219,000 | – | 9,240 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,966,038 | $282,918,000 | 60.81% |
| NEXTHERA CAPITAL LP | 1,735,030 | $30,745,000 | 5.89% |
| GREAT POINT PARTNERS LLC | 2,075,000 | $36,769,000 | 5.73% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 704,534 | $9,574,000 | 4.55% |
| Matrix Capital Management Company, LP | 10,000,000 | $177,200,000 | 4.38% |
| Consonance Capital Management LP | 3,879,050 | $68,737,000 | 3.70% |
| Rhenman & Partners Asset Management AB | 1,261,414 | $22,352,000 | 2.24% |
| BB BIOTECH AG | 2,785,000 | $49,350,000 | 1.31% |
| CAPITAL MANAGEMENT CORP /VA | 285,575 | $5,060,000 | 1.29% |
| TEALWOOD ASSET MANAGEMENT INC | 155,376 | $2,753,000 | 1.03% |